Skip to main content Accessibility help
×
Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-22T02:36:14.206Z Has data issue: false hasContentIssue false

9 - Hierarchical and Complex Pharmacotherapy Decision-Making

Published online by Cambridge University Press:  25 March 2024

Joseph F. Goldberg
Affiliation:
Icahn School of Medicine at Mount Sinai, New York
Stephen M. Stahl
Affiliation:
University of California San Diego
Get access

Summary

In preceding chapters, we have focused mainly on how to think through clinical problems that are often ambiguous or have multiple viable solutions, each with their respective pros and cons. We have deliberately refrained from offering specific recommendations about “what to do” in a given situation when no single best answer may exist. When that happens, the clinician’s task involves framing testable hypotheses and applying a reasoning process to arrive at a sensible individualized treatment regimen (ITR) for a given patient based on their unique clinical profile. Our goal has been to steer readers away from one-size-fit-all protocol-driven care and replace that approach with a more decision-analytic patient-specific iterative strategy, where nodes along a decision tree are determined by the personalized characteristics of a given individual.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aaronson, ST, Sears, P, Ruvuna, F, et al.A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: Comparison of response, remission, and suicidality. Am J Psychiatry 2017; 174: 640648CrossRefGoogle ScholarPubMed
Aklillu, E, Persson, I, Bertilsson, L, et al.Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278: 441446Google Scholar
Albert, U, Marazziti, D, Di Salvo, G, et al.A systematic review of evidence-based treatment strategies for obsessive–compulsive disorder resistant to first-line pharmacotherapy. Curr Med Chemistry 2018; 25: 56475661CrossRefGoogle ScholarPubMed
Amerio, A, Odone, A, Liapis, CC, et al.Diagnostic validity of comorbid bipolar disorder and obsessive-compulsive disorder: A systematic review. Acta Psychiatr Scand 2014; 129: 343358CrossRefGoogle ScholarPubMed
Amsterdam, JD, Berwish, NJ.High dose tranylcypromine for refractory depression. Pharmacopsychiatry 1989; 22: 2125CrossRefGoogle ScholarPubMed
Amsterdam, JD, Fawcett, J, Quitkin, FM, et al.Fluoxetine and norfluoxetine plasma concentrations in major depression: A multicenter study. Am J Psychiatry 1997; 154: 963969Google ScholarPubMed
Arnow, BA, Blasey, C, Williams, LM, et al.Depression subtypes in predicting antidepressant response: A report from the iSPOT-D trial. Am J Psychiatry 2015; 172:743750CrossRefGoogle ScholarPubMed
Barbee, JG, Thompson, TR, Jamhour, NJ, et al.A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry 2011; 72: 14051412CrossRefGoogle ScholarPubMed
Barbosa, L, Berk, M, Vorster, M.A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003; 64: 403407CrossRefGoogle ScholarPubMed
Bergeron, R, Ravindran, AV, Chaput, Y, et al.Sertraline and fluoxetine treatment of obsessive–compulsive disorder: Results of a double-blind, 6-month treatment study. J Clin Psychopharmacol 2002; 22: 148154CrossRefGoogle ScholarPubMed
Brandt, L, Bschor, T, Henssler, J, et al.Antipsychotic withdrawal symptoms: A systematic review and meta-analysis. Front Psychiatry 2020; 11: 569912CrossRefGoogle ScholarPubMed
Brunswick, DJ, Amsterdam, JD, Fawcett, J, et al.Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment. J Affect Disord 2002; 68(2–3): 243249CrossRefGoogle ScholarPubMed
Chekroud, AM, Zotti, RJ, Shehzad, Z, et al.Cross-trial prediction of treatment outcome in depression: A machine learning approach. Lancet Psychiatry 2016; 3: 343350CrossRefGoogle ScholarPubMed
Cole, EJ, Stimson, KH, Bentzley, BS, et al.Stanford Accelerated Intelligent Neuromodulation Therapy for treatment resistant depression. Am J Psychiatry 2020; 177: 716726CrossRefGoogle ScholarPubMed
Connolly, KR, Thase, ME.If at first you don’t succeed: A review of the evidence for antidepressant augmentation, combination, and switching strategies. Drugs 2011; 71: 4364CrossRefGoogle ScholarPubMed
Darab, MG, Hedayati, A, Khorasani, E, et al.Selective serotonin reuptake inhibitors in major depression disorder treatment: An umbrella review on systematic reviews. Int J Psychiatry Clin Pract 2020; 24: 357370CrossRefGoogle Scholar
De Crescenzo, F, D’Alò, GL, Ostinelli, EG, et al.Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet 2022; 400 (10347): 170184CrossRefGoogle ScholarPubMed
Dunlop, BW, Kelley, ME, Aponte-Rivera, V, et al.Effects of patient preferences on outcomes in the predictors of remission in depression to individual and combined treatments (PReDICT Study). Am J Psychiatry 2017; 174: 546556CrossRefGoogle ScholarPubMed
Dumas, R, Padovani, R, Richieri, R, et al.Repetitive transcranial magnetic stimulation in major depression: Response factor. Encephale 2012; 38: 360368CrossRefGoogle ScholarPubMed
Dunlop, BW, LoParo, D, Kinkead, B, et al.Benefits of sequentially adding cognitive–behavioral therapy or antidepressant medication for adults with nonremitting depression. Am J Psychiatry 2019; 176: 275286CrossRefGoogle ScholarPubMed
Fallon, BA, Liebowitz, MR, Campeas, R, et al.Intravenous clomipramine for obsessive–compulsive disorder refractory to oral clomipramine: A placebo-controlled study. Arch Gen Psychiatry 1998; 55: 918924CrossRefGoogle ScholarPubMed
Fava, M, Rush, AJ, Alpert, JE, et al.Differences in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report. Am J Psychiatry 2008; 165: 342351CrossRefGoogle ScholarPubMed
Fekadu, A, Wooderson, S, Donaldson, C, et al.A multidimensional tool to quantify treatment resistance in depression: The Maudsley staging method. J Clin Psychiatry 2009; 70: 177184CrossRefGoogle ScholarPubMed
Gelenberg, AJ, Kane, JM, Keller, MB, et al.Comparison of standard and low serum lithium levels for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 14891493CrossRefGoogle ScholarPubMed
Handelman, K, Sumaya, F.Tolerance to stimulant medication for attention deficit hyperactivity disorder: Literature review and case report. Brain Sci 2022; 12: 959CrossRefGoogle ScholarPubMed
Hartwell, EE, Feinn, R, Morris, PE, et al.Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction 2020; 115: 14261437CrossRefGoogle ScholarPubMed
Houston, JP, Kohler, J, Bishop, JR, et al.Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. J Clin Psychiatry 2012; 73: 10771086CrossRefGoogle ScholarPubMed
Huhn, M, Nikolakopoulou, A, Schneider-Thoma, J, et al.Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet 2019; 394: 939951CrossRefGoogle ScholarPubMed
Kahn, RS, Winder van Rossum, I, Leucht, S, et al.Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): A three-phase switching study. Lancet Psychiatry 2018; 5: 797807CrossRefGoogle ScholarPubMed
Kessler, D, Burns, A, Tallon, D, et al.Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: The MIR RTC. Health Technol Assess 2018; 22: 1136CrossRefGoogle ScholarPubMed
Koran, LM, Sallee, FR, Pallanti, S.Rapid benefit of intravenous pulse loading of clomipramine in obsessive–compulsive disorder. Am J Psychiatry 1997; 154: 396401Google ScholarPubMed
Lipkovich, I, Jacobson, JG, Hardy, TA, et al.Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry 2008; 8: 78CrossRefGoogle ScholarPubMed
Lo, H-S, Yang, C-M, Lo, HG, et al.Treatment effects of gabapentin for primary insomnia. Clin Neuropharmacol 2010; 33: 8490CrossRefGoogle ScholarPubMed
Manber, R, Buysse, DJ, Edinger, J, et al.Efficacy of cognitive–behavioral therapy for insomnia combined with antidepressant pharmacotherapy in patients with comorbid depression and insomnia: A randomized controlled trial. J Clin Psychiatry 2016; 77: e13161323CrossRefGoogle ScholarPubMed
McGrath, PJ, Stewart, JW, Fava, M, et al.Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: A STAR*D report. Am J Psychiatry 2006; 163: 15311541CrossRefGoogle ScholarPubMed
Meyer, JM.A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: Case vignettes. CNS Spectr 2014; 19: 432438CrossRefGoogle ScholarPubMed
Myer, NM, Boland, JR, Faraone, SV.Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Mol Psychiatry 2018; 23: 19291936CrossRefGoogle ScholarPubMed
Nakajima, K, Takamiya, A, Uchida, T, et al.Individual prediction of remission based on clinical features following electroconvulsive therapy: A machine learning approach. J Clin Psychiatry 2022; 83: 21m14293CrossRefGoogle ScholarPubMed
Navarro, B, Boulahva, I, Obach, A, et al.Switching to imipramine versus add-on mirtazapine in venlafaxine-resistant major depression: A 10-week randomized open study. J Clin Psychopharmacol 2019; 39: 6366CrossRefGoogle ScholarPubMed
Nelson, JC, Baumann, P, Delucchi, K, et al.A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord 2014; 168: 269275CrossRefGoogle ScholarPubMed
Ninan, PT, Koran, LM, Kiev, A, et al.High-dose sertraline strategy for nonresponders to acute treatment for obsessive–compulsive disorder: A multicenter double-blind trial. J Clin Psychiatry 2006; 67: 1522CrossRefGoogle ScholarPubMed
Noble, EP.The DRD2 gene in psychiatric and neurological disorders and its phenotypes. Pharmacogenomics 2000; 1: 309333CrossRefGoogle ScholarPubMed
Pagani, R, Gasparini, A, Ielmini, M, et al.Twenty years of lithium pharmacogenetics: A systematic review. Psychiatry Res 2019; 278: 4250CrossRefGoogle ScholarPubMed
Pangaro, LN.A new vocabulary and other innovations for improving descriptive in-training evaluations. Academic Med 1999; 74: 11CrossRefGoogle ScholarPubMed
Pigott, TA, Seay, SM.A review of the efficacy of selective serotonin reuptake inhibitors in obsessive–compulsive disorder. J Clin Psychiatry 1999; 60: 101106CrossRefGoogle ScholarPubMed
Reimherr, F, Amsterdam, J, Dunner, D, et al.Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine. Psychiatry Res 2010; 175(1–2): 6773CrossRefGoogle ScholarPubMed
Remington, G, Agid, D, Foussias, G, et al.Clozapine and therapeutic drug monitoring: Is there sufficient evidence for an upper threshold? Psychopharmacol (Berl) 2013; 225: 505518CrossRefGoogle ScholarPubMed
Roth, T, Arnold, LM, Garcia-Borreguero, D, et al.A review of the effects of pregabalin on on sleep disturbance across multiple clinical conditions. Sleep Med Rev 2014; 18: 261271CrossRefGoogle ScholarPubMed
Rush, AJ, Trivedi, MH, Stewart, JE, et al.Combining medications to enhance depression outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011; 168: 689701CrossRefGoogle ScholarPubMed
Schatzberg, AF, Blier, P, Delgado, PL, et al.Antidepressant discontinuation syndrome: Consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 2006; 67 (Suppl 4): 2730Google ScholarPubMed
Sommer, IE, Begemann, MJH, Temmerman, A, et al.Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: A quantitative literature review. Schiz Bull 2012; 38: 10031011CrossRefGoogle ScholarPubMed
Swagell, CD, Lawford, BR, Hughes, IP, et al.DRD2 C957T and TaqIA genotyping reveals gender effects and unique low-risk and high-risk genotypes in alcohol dependence. Alcohol Alcoholism 2012; 47: 397403CrossRefGoogle ScholarPubMed
Thase, ME, Rush, AJ.When at first you don’t succeed: Sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997; 58 (suppl 13): 2329Google ScholarPubMed
Thase, ME, Corya, SA, Osuntokun, O, et al.A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007; 68: 224236CrossRefGoogle ScholarPubMed
Thase, ME, Chen, D, Edwards, J, et al.Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder. Int Clin Psychopharmacol 2014; 29: 351356CrossRefGoogle ScholarPubMed
Tiihonen, J, Wahlbeck, K, Kiviniemi, V.The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis. Schizophr Res 2009; 109(1–3): 1014CrossRefGoogle ScholarPubMed
Wilens, TE, Spencer, TJ, Biederman, J, et al.A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001; 158: 282288CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×